Scientific Letters
Vol. 16 No. 1 (2024): Review Articles, Original Article, Scientific Letter, Case Reports Letter to the Editor
Impact of the Addition of Daratumumab to the Standard Bortezomib-Thalidomide-Dexamethasone Regimen on Hematopoietic Stem Cell Mobilization and Collection, Post-Transplant Engraftment and Infectious Complications: A Case-Control Multicentre Real-Life Analy
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: April 11, 2024
Accepted: April 28, 2024
Accepted: April 28, 2024
2152
Views
1010
Downloads
105
HTML
Authors
Downloads
Download data is not yet available.
Citations
How to Cite
“Impact of the Addition of Daratumumab to the Standard Bortezomib-Thalidomide-Dexamethasone Regimen on Hematopoietic Stem Cell Mobilization and Collection, Post-Transplant Engraftment and Infectious Complications: A Case-Control Multicentre Real-Life Analy” (2024) Mediterranean Journal of Hematology and Infectious Diseases, 16(1), p. e2024049. doi:10.4084/MJHID.2024.049.
Copyright (c) 2024 Gianluca Cavallaro
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
